Labcorp® Plasma Detect™ Clinical Studies Featured in Nature Medicine and Clinical Cancer Research

Provided By PR Newswire

Last update: Nov 19, 2025

Studies demonstrate Labcorp Plasma Detect MRD Technology can inform treatment strategies and advance cancer research

BURLINGTON, N.C., Nov. 19, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced Labcorp Plasma Detect, a tumor-informed, blood-based assay used to detect molecular residual disease (MRD) from circulating tumor DNA (ctDNA), was featured in two recent peer-reviewed publications – Nature Medicine and Clinical Cancer Research.